Medical Therapy Associates in Oklahoma City: Addiction Medicine with Medication-Assisted Treatment

Medical Therapy Associates operates as a private outpatient addiction treatment facility in Oklahoma City offering medication-assisted therapy (MAT) alongside counseling and behavioral services, serving adults engaged in recovery from opioid and alcohol use disorders. The practice sits in the outpatient tier of addiction medicine, distinct from residential inpatient programs and emergency detoxification units, and focuses on stable medication management paired with ongoing clinical support.

What Medical Therapy Associates actually is

The practice prescribes FDA-approved medications (methadone, buprenorphine, and naltrexone) as the clinical foundation of recovery, combined with individual counseling, group sessions, and case management. This model assumes that pharmaceutical intervention paired with behavioral work produces better long-term outcomes than abstinence-based counseling alone. The facility operates under federal certification requirements for opioid treatment programs, meaning its clinical protocols are audited and its staff must meet specific credentialing standards.

Services and medication-based therapy options

Medical Therapy Associates dispenses buprenorphine in-office and enrolls patients in buprenorphine maintenance, where individuals take the medication daily under clinical monitoring. Dosing typically begins at 4 to 8 mg daily and adjusts based on withdrawal symptoms and cravings, with many patients stabilizing between 12 and 24 mg daily. The practice also offers naltrexone therapy, a non-opioid antagonist that blocks opioid receptors, suited for patients seeking abstinence-based recovery or those unable to commit to daily medication regimens. Individual counseling sessions cost between $75 and $150 per session without insurance; group therapy averages $40 to $60 per week. Verify current fees directly, as medication costs shift with pharmacy and insurance tier changes. The practice accepts most major insurance plans, including BCBS, Cigna, and United, but out-of-pocket responsibility varies by plan design and deductible status.

Intake assessments typically run 2 to 3 hours and include clinical interview, medical history, urine drug screening, and liver function tests (standard baseline for opioid maintenance). Patients stabilize on medication over 2 to 4 weeks while attending weekly counseling; after stabilization, appointments may decrease to twice monthly for routine follow-ups.

How Medical Therapy Associates compares to other Oklahoma City addiction medicine options

Methadone programs in Oklahoma City, such as those operated through federally qualified health centers (FQHCs), offer lower-cost daily dispensing ($10 to $15 per day for uninsured patients), but methadone requires daily in-person visits because of federal dispensing restrictions, whereas buprenorphine through Medical Therapy Associates allows for prescription refills at community pharmacies once stabilized. Residential programs like Sunbeam Family Services' inpatient detoxification unit suit acute withdrawal or unsafe home environments but cost $800 to $2000 per day; Medical Therapy Associates addresses outpatient chronic care and is more appropriate for individuals with stable housing and employment.

Choose Medical Therapy Associates if you work a regular schedule and need flexible appointment spacing after initial stabilization, or if you prefer buprenorphine's lower overdose risk compared to methadone. Methadone programs in Oklahoma City are better if transportation to daily dispensing is feasible and cost reduction is the primary driver. Residential detox is necessary when acute withdrawal symptoms are severe, psychiatric comorbidities are unmanaged, or the patient is at imminent risk.

Who this place suits and who it does not

Medical Therapy Associates fits individuals with opioid use disorder who are employed, housed, and motivated to take oral medication as prescribed; patients with significant psychiatric illness (untreated bipolar disorder, active psychosis) who cannot engage in concurrent mental health treatment elsewhere will not succeed because the practice focuses on addiction medicine rather than psychiatric stabilization. People with active alcohol use disorder as the primary diagnosis may be less optimal candidates because buprenorphine and naltrexone are secondary interventions for alcohol and require parallel treatment in a dual-diagnosis program. Patients unwilling to attend weekly counseling or undergo regular drug screening are not appropriate fits; the model rests on both medication and behavioral accountability.

What the first visit involves

The initial appointment requires 2 to 3 hours and addresses clinical history, current substance use patterns, previous treatment attempts, medical comorbidities, and psychiatric symptoms. Expect a urine drug screen, liver enzyme labs (AST, ALT, bilirubin), hepatitis C and HIV screening if not recently documented, and an EKG if age or cardiac symptoms warrant it. The prescriber explains medication mechanism, expected timeline to stabilization (usually 2 to 4 weeks), withdrawal symptom patterns, and medication side effects (constipation is common with opioid agonists; insomnia and dysphoria with naltrexone). A counselor or case manager discusses treatment goals, establishes appointment frequency, and reviews insurance benefits and out-of-pocket costs. Bring a government-issued ID, proof of insurance or documentation of income if uninsured, and a list of current medications and supplements.

Hours, parking, and logistics

Medical Therapy Associates operates Monday through Friday, 8:00 am to 5:00 pm, with no weekend or evening hours. Parking is available in the clinic lot. The practice does not offer medication dispensing on Saturdays, meaning patients must plan medication pickup at a community pharmacy on weekdays or arrange alternate supply if unable to attend an appointment. Confirm current hours directly because clinical schedules may shift seasonally.

Medical Therapy Associates fills a necessary clinical niche in Oklahoma City for working-age adults whose recovery depends on stable medication plus ongoing accountability, and its buprenorphine model reduces barriers to daily dosing compared to methadone programs while maintaining clinical oversight.